Navigation Links
Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
Date:6/22/2013

ster #74-LB, investigators analyzed the data pooled from the same four phase III studies to evaluate events consistent with UTIs and genital infections.2

The safety results with empagliflozin included:

  • Incidence of UTIs comparable to placebo (9.3 percent and 7.5 percent for 10 mg and 25 mg, respectively, vs. 8.2 percent for placebo)2
    • <10 percent of patients experienced more than one event 2
    • Of the reported UTI episodes, most were mild in intensity
      • Mild: 7.5 percent for 10 mg; 6.7 percent for 25 mg, and 6.9 percent for placebo
      • Moderate: 1.7 percent for 10 mg; 0.9 percent for 25 mg, and 1.1 percent for placebo
      • Severe: 0.1 percent for 10 mg; 0 percent for 25 mg, and 0.2 percent for placebo
    • Low discontinuation rates (0.2 percent, 10 mg; 0.1 percent, 25 mg; 0.1 percent, placebo)2
  • Incidence of genital infections higher than placebo (4.2 percent and 3.6 percent for 10 mg and 25 mg, respectively, vs. 0.7 percent for placebo)2
    • <5 percent of patients experienced more than one event2
    • Most episodes were mild (2.9 percent, 10 mg; 2.4 percent, 25 mg; 0.6 percent, placebo) to moderate (1.3 percent, 10 mg; 1.2 percent, 25 mg; 0.1 percent, placebo) in intensity2
    • Low discontinuation rates (0.1 percent, 10 mg; 0.2 percent, 25 mg; 0 percent, placebo)2

About the Empagliflozin Phase III Clinical Trial Program
Empagliflozin is being investigated in adults with T2D in a phase III clinical trial program that has enrolled more than 14,500 people. In total, this program includes more than 10 multinational clinical trials, including a large cardiovascular outcomes trial.

Abo
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
2. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
3. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
4. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
5. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
6. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
9. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
10. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
11. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Colo. , Nov. 25, 2014 /PRNewswire/ ... ) today announced that its Chief Executive ... at the following upcoming conferences.  The public ... through webcasts on the Array BioPharma website:  ... December 3, 2014Time:1:30 p.m.  Eastern Time Location: ...
(Date:11/26/2014)... Nov. 25, 2014 Immune Pharmaceuticals Inc. ... stage biopharmaceutical company that engages in the development ... of inflammatory diseases and cancer, today announced the ... of 3,450,000 units, with each unit consisting of ... value $0.0001 per share, and one warrant to ...
(Date:11/24/2014)...  CryoLife, Inc. (NYSE: CRY ), a leading ... vascular surgery, announced today that it will participate in the ... Wednesday, December 3, 2014 at The New York Palace Hotel ... A live webcast of the Company,s presentation is scheduled to ... of the company by Pat Mackin , President and ...
Breaking Medicine Technology:Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3
(Date:11/26/2014)... Dr. Parsa Mohebi is giving prospective ... With Parsa Mohebi Hair Restoration’s new winter special, patients ... FUE procedure, making it that much easier to get ... Unit Extraction”—is an advanced variety of hair restoration surgery ... Transplantation (FUT). FUE, unlike FUT, does not leave a ...
(Date:11/26/2014)... 27, 2014 Recently, Locks-Magnetic.com, a Chinese ... collection of magnetic locks on the Internet. It also ... until December. , As a leading company in ... for worldwide customers to buy high quality locks. It ... it provides locks that are not only useful but ...
(Date:11/26/2014)... (PRWEB) November 27, 2014 Boxing Day ... and tradesmen would receive gifts, known as a "Christmas ... Wikipedia ) , With the coming of Boxing Day, ... Tbdress.com is smart before every business opportunity, and it ... ”, offering a site-wide promotion for its global customers. ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Pharmaceutical ... humidity, and pressure levels during manufacturing and research ... and air conditioning) systems play a key role. ... microorganisms or bio-contaminants, while humidity can affect the ... The use of HVAC systems helps to address ...
(Date:11/26/2014)... Dallas, Texas (PRWEB) November 26, 2014 ... surgeon and Distinguished Teaching Professor in the ... Center, recently discussed facial fat compartments, fat grafting, ... Surgery, The Meeting," an annual conference held by ... importance and intricacies of this underlying facial structure ...
Breaking Medicine News(10 mins):Health News:FUE Special at Parsa Mohebi Hair Restoration This Holiday Season 2Health News:Fresh Products Launched by Famous Company Lock-Magnetic.com 2Health News:Tbdress.com: Best Boxing Day Sales For Ladies Worldwide 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 5Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 2Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 3
... Socit de Pathologie Exotique , launched shortly after the ... and English as well as meeting reports. Today, ... and is recognized for its impressive collection of tropical ... students, the Bulletin appears five times per year and ...
... suggests that exempting bars from community smoking bans makes ... and that even the most comprehensive clean indoor air ... jobs. , Researchers hope the findings, based on a ... municipalities and states considering the economic and health issues ...
... Equality,s Judicial Victory Leads to Legislative ... Guardianship CHICAGO, May 18 Today, the Illinois ... adults with disabilities under guardianship without due process. ... disabilities under guardianship has been preserved. The bill, ...
... into State-of-the-Art Neonatal Intensive Care Unit WASHINGTON, May ... home at Children,s National Medical Center. The new, ... when the babies were transported from the hospital,s ... http://www.newscom.com/cgi-bin/prnh/20090518/DC18562 )"This NICU was ...
... Now Available for Use in Clinical Trials and Population Health ... vital to health and well-being as a good night,s sleep. ... the National Sleep Foundation -- suffer from chronic sleep problems ... showing correlations between poor or insufficient sleep and disease. Now ...
... resource from ACTS Retirement-Life Communities helps consumers ask the right questions ... ... West Point, PA (Vocus) May 18, 2009 -- Preparing ... many factors to consider, including present and future needs, personal preferences, ...
Cached Medicine News:Health News:Study: Smoking bans do not cause job losses in bars and restaurants 2Health News:Study: Smoking bans do not cause job losses in bars and restaurants 3Health News:Study: Smoking bans do not cause job losses in bars and restaurants 4Health News:Passage of Illinois House Bill 2290 Adds Crucial Due Process Protection Governing Sterilization of Adults With Disabilities 2Health News:Passage of Illinois House Bill 2290 Adds Crucial Due Process Protection Governing Sterilization of Adults With Disabilities 3Health News:The Most Fragile Babies in the Nation's Capital Have a New Home 2Health News:QualityMetric Offers Way to Measure the Impact of Sleep Problems on Individuals and Groups 2Health News:7 Tips for Choosing a Retirement Community 2Health News:7 Tips for Choosing a Retirement Community 3
Maltzman-Fenzl lens manipulator, V shaped tip, straight. Also available in titanium....
0.3 mm diameter hemi-ball tip....
Vaulted shank with guard....
... individually adjusted for perfect focus where it's ... paper. This, along with Keeler's wide angle ... whatever the patient's pupil size, you will ... view. Lithium-ion technology provides a longer life ...
Medicine Products: